Medicine
Vitamin E tocotrienols may improve rheumatoid arthritis
|
Ainhoa Pérez
Alumni
|
|
MPH, MSc.
|
Tocotrienols, active forms of vitamin E with high anti-inflammatory potential, may be useful in the adjunctive treatment of rheumatoid arthritis. A recent clinical trial evaluated their effect on disease activity, pain, and inflammatory markers. In this article, we discuss the potential effect and limitations of the study.
PATHOPHYSIOLOGY AND MECHANISMS
Rheumatoid arthritis is a chronic autoimmune inflammatory disease that causes persistent joint inflammation, pain, functional impairment, and progressive joint destruction. Its pathophysiology involves the dysregulated activation of the immune system with the presence of autoantibodies against citrullinated proteins and the release of proinflammatory cytokines such as TNF-a, IL-1, and IL-6, producing systemic inflammation and tissue damage. Conventional treatment, usually based on disease-modifying drugs, nonsteroidal anti-inflammatory drugs, and corticosteroids, has therapeutic limitations and long-term adverse effects. Tocotrienols are a group of various forms of vitamin E with greater antioxidant and anti-inflammatory activity than other forms of vitamin E such as tocopherols. Tocotrienols may act by inhibiting the NF-kB pathway, reducing the expression of pro-inflammatory genes and cytokine production. In addition, they may modulate the activation of T lymphocytes and macrophages, as well as neutralize reactive oxygen species, reducing oxidative damage. They also reduce arachidonic acid-derived mediators, which could attenuate inflammation and joint pain.STUDY
A randomized, double-blind, placebo-controlled clinical trial (Zainal et al., 2025) evaluated the effects of a supplement rich in tocotrienoles in 50 adults with moderate rheumatoid arthritis. Participants were assigned to receive 400 mg daily of the tocotrienol-rich supplement or a placebo for six months. Both groups maintained stable doses of antirheumatic drugs. Clinical and biochemical assessments were performed at baseline, 1, 3, and 6 months. Additionally, a 3-month follow-up was conducted after the intervention. The main variables analyzed included DAS28-CRP, number of painful and swollen joints, C-reactive protein, erythrocyte sedimentation rate, and visual analog scale for pain. Adherence was monitored through records and capsule counts.MAIN RESULTS
The results showed that the group supplemented with tocotrienols experienced a clinically significant reduction in the clinical activity of rheumatoid arthritis, evidenced by a decrease in the DAS28-CRP score from the first month, with particularly marked differences compared to the control group at six months, and the trend was maintained in the following three months of follow-up. In the tocotrienol-supplemented group, the analysis identified that the reduction in clinical activity was significantly associated with a decrease in pain, as assessed by visual analog scale, painful joints, and swollen joints. C-reactive protein levels and erythrocyte sedimentation rate also decreased progressively in the intervention group. No adverse effects associated with the intervention were reported, and high adherence was achieved with a low dropout rate.CONCLUSION AND CLINICAL RELEVANCE
These results suggest that tocotrienols may have a significant positive effect as an adjunct in the treatment of rheumatoid arthritis. There is previous preclinical and clinical evidence on the anti-inflammatory and antioxidant effects of tocotrienols. There are also several studies suggesting some analgesic potential for vitamin E, although there are not many specific clinical trials in rheumatoid arthritis. It should be noted that studies with vitamin E may include multiple forms of tocopherols, tocotrienols, and other forms of vitamin E, which have wide differences in their anti-inflammatory effect, making it difficult to interpret the effect observed in clinical trials. However, there are important limitations to this study. The product used, in addition to tocotrienols and a smaller percentage of tocopherols, also included several phytochemicals that may exert anti-inflammatory, antioxidant, and bioavailability-modulating effects, thus making it difficult to attribute the results exclusively to tocotrienols. The study outcomes are largely subjective (such as the VAS, TJC, and SJC included in the DAS28), so blinding of the evaluator is essential. However, this is not clearly described in the article, so in a risk of bias analysis it would be assessed as high, or at least uncertain. Therefore, although the results of this study suggest a possible benefit, the evidence is still limited to make a firm recommendation for vitamin E in this condition. Additionally, it should be noted that in this type of condition, the greatest effect on symptoms is expected with comprehensive anti-inflammatory nutritional management, not through the use of a single supplement.
#vitamins #tocotrienols #tocopherols #rheumatoidarthritis #pain #autoimmunediseases
References:
Zainal, Z et al, 2025. Reduction of disease activity in rheumatoid arthritis by tocotrienol-rich fraction supplementation: a randomized, double-blind, placebo-controlled trial. European Journal of Nutrition, 64(227). https://doi.org/10.1007/s00394-025-03742-6
* The news published on studies do not represent an official position of ICNS, nor a clinical recommendation.
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
